Affimed N.V EV/EBIT
¿Qué es el EV/EBIT de Affimed N.V?
El EV/EBIT de Affimed N.V. es N/A
¿Cuál es la definición de EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT de compañías en Sector Health Care en NASDAQ en comparadas con Affimed N.V
¿Qué hace Affimed N.V?
affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli
Empresas con ev/ebit similar a Affimed N.V
- CytomX Therapeutics Inc tiene EV/EBIT de N/A
- Ansal Housing & Construction tiene EV/EBIT de N/A
- Teligent Inc tiene EV/EBIT de N/A
- MedinCell S.A tiene EV/EBIT de N/A
- ECR Minerals Plc tiene EV/EBIT de N/A
- Rincon Resources tiene EV/EBIT de N/A
- Affimed N.V tiene EV/EBIT de N/A
- Scienjoy tiene EV/EBIT de N/A
- Mafatlal Industries tiene EV/EBIT de N/A
- Indus tiene EV/EBIT de N/A
- King George tiene EV/EBIT de N/A
- Crossover Acquisitions tiene EV/EBIT de N/A
- Green Hygienics tiene EV/EBIT de N/A